RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. on October 16, 2014. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding the exercise of Series A Warrants issued in May and June 2014.
Key Financial Metrics
The filing announces the receipt of gross proceeds from the exercise of Series A Warrants. However, the specific dollar amount of these proceeds is not stated within the text of this Form 8-K; the document refers to an attached press release (Exhibit 99.1) for the detailed figures. No other financial metrics, including revenue, profit, cash flow, margins, debt, or liquidity, are provided in this specific filing.
Material Changes
The material change reported is the capital raise resulting from the exercise of previously issued Series A Warrants. This event increases the company's cash position, though the exact magnitude is not quantified in the body of this report.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the standard disclosure language. The information is furnished under Regulation FD and is not deemed "filed" for purposes of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) to determine the exact gross proceeds received from the warrant exercise.
- Verify the number of shares issued upon the exercise of the Series A Warrants.
- Confirm the impact of this capital raise on the company's total cash balance and runway.
- Check subsequent filings for any updated financial statements reflecting this transaction.